Summary
The provided AI claims evaluate an acetaminophen/aspirin combination, but the FDA label supplied in the prompt is for CODRIX™ (codeine phosphate + acetaminophen). None of the aspirin-specific dose/safety interaction/contraindication guidance is supported by the provided CODRIX label excerpts, creating widespread unsupported and potentially unsafe misalignment.
Category Scores
Accurate Statements
The FDA label excerpt provided for CODRIX™ indicates it is for the relief of mild to moderately severe pain.
CODRIX label Section 1: “CODRIX™ is indicated for the relief of mild to moderately severe pain.”
Unsupported Statements
Acetaminophen (Tylenol) and aspirin can generally be taken together safely for short-term pain or fever relief in healthy adults at recommended doses.
No aspirin information, combination guidance, or fever indication is present in the provided CODRIX (codeine/acetaminophen) label excerpts.
Acetaminophen dosing up to 4,000 mg/day is recommended (when taking acetaminophen).
The provided CODRIX label includes acetaminophen maximum dosing within the codeine/acetaminophen regimen, not as a standalone acetaminophen/aspirin product recommendation; aspirin-specific context is unsupported.
Aspirin dosing up to 4,000 mg/day is recommended (when taking aspirin).
Aspirin dosing is not present in the provided CODRIX label excerpts.
It is recommended not to exceed 10 days of use without medical advice.
No 10-day limit for this product is provided in the supplied excerpts (and no aspirin/acetaminophen combination label content is provided).
Acetaminophen targets the brain's pain and fever centers.
This mechanism statement is not supported by the supplied CODRIX label excerpts.
Aspirin blocks COX enzymes to reduce inflammation, pain, and clotting.
Aspirin mechanism is not addressed in the supplied CODRIX label excerpts.
No direct pharmacokinetic interactions occur between acetaminophen and aspirin.
The provided label excerpts do not discuss acetaminophen-aspirin pharmacokinetic interactions.
Overdose of acetaminophen increases the risk of liver damage.
The provided CODRIX excerpts do not include this specific overdose/toxicity-liver claim.
Aspirin increases the risk of stomach bleeding or ulcers due to its antiplatelet effects.
No aspirin-related GI bleeding/ulcer warning is present in the supplied CODRIX label excerpts.
The risk of stomach bleeding or ulcers from aspirin is higher with alcohol or NSAID use.
No aspirin GI bleeding/ulcer risk stratification is present in the supplied CODRIX label excerpts.
Aspirin may cause kidney strain in those with pre-existing conditions.
No aspirin renal warning is present in the supplied CODRIX label excerpts.
High doses of the combination amplify gastrointestinal irritation.
No aspirin/acetaminophen combination GI irritation warning is present in the supplied CODRIX label excerpts.
Rare allergic reactions can occur with this combination.
While the CODRIX label lists allergic reactions generally, it does not support an “aspirin/acetaminophen combination” statement.
Reye's syndrome in children/teens with viral infections makes the combination off-limits for them.
No aspirin/children/Reye’s syndrome warning is present in the supplied CODRIX label excerpts.
People with liver disease should avoid this combination.
The supplied CODRIX label excerpt mentions caution in severe impairment of renal or hepatic function but does not support “avoid this combination” (and does not describe an aspirin/acetaminophen combination).
People with heavy alcohol use should avoid this combination.
The supplied CODRIX label mentions enhanced CNS depression with alcohol, but does not support an “avoid the acetaminophen/aspirin combination” claim.
People with peptic ulcers should avoid this combination.
No aspirin/ulcer contraindication is present in the supplied CODRIX label excerpts.
People with bleeding disorders should avoid this combination.
No aspirin/bleeding disorder guidance is present in the supplied CODRIX label excerpts.
People with aspirin-sensitive asthma should avoid this combination.
No aspirin-sensitive asthma guidance is present in the supplied CODRIX label excerpts.
People on blood thinners like warfarin should consult a doctor before using this combination.
No warfarin/blood thinner interaction guidance is present in the supplied CODRIX label excerpts.
This combination is not recommended during pregnancy.
The supplied CODRIX excerpts do not address pregnancy recommendations.
During pregnancy, aspirin is specifically not recommended in the third trimester.
No aspirin pregnancy trimester guidance is present in the supplied CODRIX label excerpts.
During breastfeeding, acetaminophen and aspirin use is not recommended without guidance.
No breastfeeding guidance is present in the supplied CODRIX label excerpts, and aspirin-specific content is absent.
Children under 16 should avoid aspirin entirely.
No aspirin pediatric age restriction is present in the supplied CODRIX label excerpts.
Doses of acetaminophen and aspirin should be spaced 4–6 hours apart when taken together.
No aspirin/acetaminophen spacing instruction is present in the supplied CODRIX label excerpts.
Total daily intake should be tracked to stay under daily limits.
While CODRIX includes maximum daily doses in the table (acetaminophen 4000 mg; codeine 360 mg), the supplied excerpts do not support a general “track total daily intake” instruction for an aspirin/acetaminophen combination.
An example regimen is 500 mg acetaminophen plus 325 mg aspirin every 6 hours.
Aspirin-containing example dosing is not present in the supplied CODRIX label excerpts.
The example regimen allows a maximum of 4 doses per day.
This depends on aspirin example dosing and is not supported by the provided CODRIX label excerpts.
Use of enteric-coated aspirin can cut stomach upset.
No aspirin formulation guidance is present in the supplied CODRIX label excerpts.
The combination should be stopped if stomach pain, black stools, or jaundice appears.
No aspirin/acetaminophen combination stop-guidance or those specific symptoms are present in the supplied CODRIX label excerpts.
Compared with acetaminophen-ibuprofen, aspirin-acetaminophen carries more bleeding risk.
No comparative NSAID/aspirin bleeding-risk statement is present in the supplied CODRIX label excerpts.
Acetaminophen-ibuprofen is described as also safe short-term and better for inflammation.
No ibuprofen comparative safety/inflammation guidance is present in the supplied CODRIX label excerpts.
Aspirin-acetaminophen adds anti-inflammatory effects.
No aspirin-related anti-inflammatory claim is present in the supplied CODRIX label excerpts.
This combination should be avoided with other NSAIDs.
No aspirin/acetaminophen + other NSAIDs avoidance guidance is present in the supplied CODRIX label excerpts.
This combination should be avoided with high-dose acetaminophen products.
No aspirin/acetaminophen combination avoidance with “high-dose acetaminophen products” is present in the supplied CODRIX label excerpts.
Avoiding combining is advised for fever in children, and alternating beats combining for fever in kids per AAP guidelines.
No pediatric fever/“alternating” guidance or any AAP guideline reference is present in the supplied CODRIX label excerpts.
If pain lasts over 10 days, a doctor should be consulted.
No 10-day pain duration consult guidance is present in the supplied CODRIX label excerpts.
If fever lasts over 3 days, a doctor should be consulted.
CODRIX label excerpt provided does not address fever duration consult, nor any aspirin/acetaminophen fever guidance.
Severe headache, rash, or swelling after taking these medications indicates a need to see a doctor.
The supplied CODRIX label excerpts list adverse reactions including allergic reactions/rash but do not provide this specific “see a doctor” instruction tied to aspirin/acetaminophen.
Overdose signs such as nausea and confusion require immediate ER care.
No overdose symptom list or emergency-care instruction is present in the supplied CODRIX label excerpts.
Acetaminophen toxicity peaks at 7.5–10 g.
No such numeric “peaks at 7.5–10 g” statement is present in the supplied CODRIX label excerpts.
This FDA-approved prescribing information is for CODRIX (codeine phosphate + acetaminophen), not acetaminophen/aspirin; therefore aspirin-specific claims may not apply.
This is a meta-statement not present in the AI claims list; however, the overall set of claims is aspirin/acetaminophen oriented and not supported by the provided CODRIX labeling.
Contradictions
Important Omissions
CODRIX-specific contraindication content should be addressed (hypersensitivity to codeine or acetaminophen).
Importance:
High
CODRIX-specific warnings (e.g., respiratory depressant enhancement with head injury/intracranial lesions; habit-forming/abusable; caution in elderly/debilitated/severe renal/hepatic impairment) are not considered.
Importance:
High
CODRIX-specific adverse reactions (drowsiness, lightheadedness, dizziness, sedation, shortness of breath, nausea/vomiting; plus constipation, abdominal pain, rash, etc.) are not evaluated.
Importance:
High
CODRIX interaction guidance (enhanced effects with alcohol and other CNS depressants) is not assessed against the provided label content.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes extensive aspirin-specific dosing and safety assertions that are not supported by the provided CODRIX (codeine/acetaminophen) prescribing information excerpts, increasing the likelihood of incorrect medication guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Mismatch between evaluated drug/label (CODRIX: codeine + acetaminophen) and the response claims (acetaminophen + aspirin), with widespread unsupported aspirin-specific safety/dosing statements.
Suggested Improvement
Evaluate and report claims strictly using the provided CODRIX label excerpts (Sections 1, 2, 4, 5, 6, 12). Remove aspirin/aspirin-dosing/fever/Reye’s/pregnancy-third-trimester/enteric-coated/GI bleed comparative NSAID statements unless the corresponding CODRIX label content is provided and explicitly supports them.